StockData
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. (AVTX) stock

AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$7.13−0.24 (-3.26%)

Close on Nov 17, 2026Market cap $382.38MP/E –Yield –

Avalo Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Avalo Therapeutics's price to sales ratio was 118.3× on Apr 30, 2025, against 7.1× a year earlier. Over the last 5 years it ranged from 0.1× to 190.2×, with a median of 15.1×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Apr 30, 2025118.3×+30.5
2024Dec 31, 202487.7×+84.5
2023Dec 29, 20233.2×+0.5
2022Dec 30, 20222.7×−25.9
2021Dec 31, 202128.6×−5.6
2020Dec 31, 202034.2×+12.9
2019Dec 31, 201921.3×+12.7
2018Dec 31, 20188.6×+5.4
2017Dec 29, 20173.2×–

More Avalo Therapeutics figures

See a number that looks wrong?